Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Small molecule scaffolds that disrupt the Rev1-CT/RIR protein-protein interaction.

Ozen Z, Dash RC, McCarthy KR, Chow SA, Rizzo AA, Korzhnev DM, Hadden MK.

Bioorg Med Chem. 2018 Aug 7;26(14):4301-4309. doi: 10.1016/j.bmc.2018.07.029. Epub 2018 Jul 19.

PMID:
30037752
2.

Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.

Song L, Ding S, Ge Z, Zhu X, Qiu C, Wang Y, Lai E, Yang W, Sun Y, Chow SA, Yu L.

Br J Pharmacol. 2018 Apr;175(8):1241-1259. doi: 10.1111/bph.14036. Epub 2017 Oct 25.

3.

Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication.

Tekeste SS, Wilkinson TA, Weiner EM, Xu X, Miller JT, Le Grice SF, Clubb RT, Chow SA.

J Virol. 2015 Dec;89(23):12058-69. doi: 10.1128/JVI.01471-15. Epub 2015 Sep 23.

4.

Dynamics of HSPC repopulation in nonhuman primates revealed by a decade-long clonal-tracking study.

Kim S, Kim N, Presson AP, Metzger ME, Bonifacino AC, Sehl M, Chow SA, Crooks GM, Dunbar CE, An DS, Donahue RE, Chen IS.

Cell Stem Cell. 2014 Apr 3;14(4):473-85. doi: 10.1016/j.stem.2013.12.012.

5.

Analysis of single-nucleotide polymorphisms in patient-derived retrovirus integration sites reveals contamination from cell lines acutely infected by xenotropic murine leukemia virus-related virus.

Rusmevichientong A, Das Gupta J, Elias PS, Silverman RH, Chow SA.

J Virol. 2011 Dec;85(23):12830-4. doi: 10.1128/JVI.05624-11. Epub 2011 Sep 21.

6.

Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.

Kim S, Kim YC, Qi H, Su K, Morrison SL, Chow SA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5090-8. doi: 10.1128/AAC.00687-11. Epub 2011 Aug 29.

7.

The nuclear pore complex: a new dynamic in HIV-1 replication.

Woodward CL, Chow SA.

Nucleus. 2010 Jan-Feb;1(1):18-22. doi: 10.4161/nucl.1.1.10571.

8.

High-throughput, sensitive quantification of repopulating hematopoietic stem cell clones.

Kim S, Kim N, Presson AP, An DS, Mao SH, Bonifacino AC, Donahue RE, Chow SA, Chen IS.

J Virol. 2010 Nov;84(22):11771-80. doi: 10.1128/JVI.01355-10. Epub 2010 Sep 15.

9.

A new functional role of HIV-1 integrase during uncoating of the viral core.

Briones MS, Chow SA.

Immunol Res. 2010 Dec;48(1-3):14-26. doi: 10.1007/s12026-010-8164-z.

PMID:
20721640
10.

Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease.

Rusmevichientong A, Chow SA.

Immunol Res. 2010 Dec;48(1-3):27-39. doi: 10.1007/s12026-010-8165-y.

PMID:
20717743
11.

Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus.

Kim S, Rusmevichientong A, Dong B, Remenyi R, Silverman RH, Chow SA.

PLoS One. 2010 Apr 20;5(4):e10255. doi: 10.1371/journal.pone.0010255.

12.

Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core.

Briones MS, Dobard CW, Chow SA.

J Virol. 2010 May;84(10):5181-90. doi: 10.1128/JVI.02382-09. Epub 2010 Mar 10.

13.

Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1.

Woodward CL, Prakobwanakit S, Mosessian S, Chow SA.

J Virol. 2009 Jul;83(13):6522-33. doi: 10.1128/JVI.02061-08. Epub 2009 Apr 15.

14.

Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells.

Vatakis DN, Kim S, Kim N, Chow SA, Zack JA.

J Virol. 2009 Jun;83(12):6222-33. doi: 10.1128/JVI.00356-09. Epub 2009 Apr 15.

15.
16.

Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase.

Wilkinson TA, Januszyk K, Phillips ML, Tekeste SS, Zhang M, Miller JT, Le Grice SF, Clubb RT, Chow SA.

J Biol Chem. 2009 Mar 20;284(12):7931-9. doi: 10.1074/jbc.M806241200. Epub 2009 Jan 16.

17.

Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C, Klein EA, Lee C, Silverman RH, Chow SA.

J Virol. 2008 Oct;82(20):9964-77. doi: 10.1128/JVI.01299-08. Epub 2008 Aug 6.

18.
19.

An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH.

Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60. Epub 2007 Jan 18.

20.

Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.

Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA.

J Virol. 2007 Apr;81(7):3574-82. Epub 2007 Jan 17.

21.

A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites.

Kim S, Kim Y, Liang T, Sinsheimer JS, Chow SA.

J Virol. 2006 Nov;80(22):11313-21. Epub 2006 Sep 13.

23.

Rapid size dependent deletion of foreign gene sequences inserted into attenuated HIV-1 upon infection in vivo: implications for vaccine development.

Brooks DG, Cohen MD, Jamieson BD, Poon B, Kitchen SG, Chow SA, Chen IS, Zack JA, Koka PS.

Curr HIV Res. 2005 Oct;3(4):377-92.

PMID:
16250884
26.
27.
30.

Molecular genetics and target site specificity of retroviral integration.

Holmes-Son ML, Appa RS, Chow SA.

Adv Genet. 2001;43:33-69. Review.

PMID:
11037298
31.

Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids.

Zhu K, Cordeiro ML, Atienza J, Robinson WE Jr, Chow SA.

J Virol. 1999 Apr;73(4):3309-16.

32.
33.

Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair.

Withers-Ward ES, Jowett JB, Stewart SA, Xie YM, Garfinkel A, Shibagaki Y, Chow SA, Shah N, Hanaoka F, Sawitz DG, Armstrong RW, Souza LM, Chen IS.

J Virol. 1997 Dec;71(12):9732-42.

34.

In vitro assays for activities of retroviral integrase.

Chow SA.

Methods. 1997 Aug;12(4):306-17.

PMID:
9245611
35.

Characterization of feline immunodeficiency virus integrase and analysis of functional domains.

Shibagaki Y, Holmes ML, Appa RS, Chow SA.

Virology. 1997 Mar 31;230(1):1-10.

36.

Central core domain of retroviral integrase is responsible for target site selection.

Shibagaki Y, Chow SA.

J Biol Chem. 1997 Mar 28;272(13):8361-9.

37.
38.

Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.

Robinson WE Jr, Cordeiro M, Abdel-Malek S, Jia Q, Chow SA, Reinecke MG, Mitchell WM.

Mol Pharmacol. 1996 Oct;50(4):846-55.

PMID:
8863829
39.

Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Robinson WE Jr, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA.

Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6326-31.

44.

Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus.

Chow SA, Vincent KA, Ellison V, Brown PO.

Science. 1992 Feb 7;255(5045):723-6.

PMID:
1738845
45.
46.
47.

Postnatal changes in the insulin-depleting action and disposition of cyproheptadine in rats.

Chow SA, Fischer LJ.

Dev Pharmacol Ther. 1991;16(3):150-63.

PMID:
1914789
49.
50.

Evidence that drug metabolites are involved in cyproheptadine-induced loss of pancreatic insulin.

Chow SA, Rickert DE, Fischer LJ.

J Pharmacol Exp Ther. 1988 Jul;246(1):143-9.

PMID:
3292756

Supplemental Content

Support Center